openPR Logo
Press release

Radiation-Induced Myelosuppression Treatment Market Opportunity Analysis by 2028 | Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC, Amgen Inc., Mylan NV, Novartis AG, and Partner Therapeutics

01-30-2019 12:55 PM CET | Health & Medicine

Press release from: Future Market Insights

Radiation-Induced Myelosuppression Treatment Market

Rapidly improving healthcare infrastructure and reimbursement scenario has been a major booster for the healthcare industry in developing regional markets. With incessantly increasing number of cancer cases, it is more likely that the subsequent demand for a wide range of treatments adopted to treat cancer patients would also remain on a constant rise over the course of coming years.

Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.

A new market research study on global radiation-induced myelosuppression treatment forecasts steady growth for the market in the next few years. Future Market Insights projects a moderate, just-under 4% yearly growth outlook, in 2019 and ahead.

Nutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opporunities for radiation-induced myelosuppression treatment providers.

Get Sample Copy of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

Report tracks key factors driving revenue growth of the market -

Increasing prevalence of cancers

Early diagnosis, promising improved chances of positive outcomes

Fostering R&D funds supporting cancer research

Strong product pipeline

Bolstering adoption of chemo-radiotherapy in cancer treatment

In the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.

Myelo001 by Myelo Therapeutics GmbH recently received an FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.

Mylan NV and Pfizer Inc. also reveived FDA approvals for their recently launched biosimilars - Epogen and Neupogen, and Neulasta respectively.

Patent expiry of originator biologics formulations is creating investment opportunities in biosimilars production – for the operators in radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.

Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the radiation-induced myelosuppression treatment market in the region. North America will reportedly continue to account for over 65% share in the global market value.

New product launches currently mark the top developmental strategy adopted by leading companies competing in the radiation-induced myelosuppression treatment market. A majority of key players are also identified to focus on enhancing their geographical foothold in global radiation-induced myelosuppression treatment landscape. The report in a distinct section covers some of the key competitors operating in radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.

A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.

Request Customized Copy of Report @ https://www.futuremarketinsights.com/customization-available/rep-gb-8116

In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, in an effort to achieve better penetration into regional markets.

About Us

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us

U.S. Office

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.com

Web: https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Radiation-Induced Myelosuppression Treatment Market Opportunity Analysis by 2028 | Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC, Amgen Inc., Mylan NV, Novartis AG, and Partner Therapeutics here

News-ID: 1546173 • Views:

More Releases from Future Market Insights

Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Million by 2032
Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Milli …
The lithium-ion battery separator is a critical component in lithium-ion batteries, responsible for preventing short circuits and ensuring safe and efficient battery performance. It acts as a physical barrier between the positive and negative electrodes, allowing lithium ions to pass through while blocking the flow of electrons. With advancements in separator technology, these separators play a key role in enhancing battery capacity, cycle life, and overall safety in various applications,
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolstered by a Robust 7.1% CAGR from 2022
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolst …
The Industrial Drums Market is experiencing a steady and promising trajectory, with an estimated value of US$ 12.5 billion in 2022, projected to escalate to US$ 17.6 billion by 2027 at a commendable Compound Annual Growth Rate (CAGR) of 7.1%. This growth is substantiated by a 6.6% CAGR in volume during 2022-27, as per Future Market Insights. Anticipated to expand 1.5 times within this period, the market presents alluring prospects for industry
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of the Metal Cans Industry, Catering to Health-conscious and Environmentally-aware Consumers
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of …
The metal cans market is predicted to grow at a CAGR of 5% over the forecast period, according to research by Future Market Insights. The industry's estimated value is expected to increase from US$ 56 Bn in 2023 to US$ 91.1 Bn by 2033. The market for metal cans has been driven by the heightened demand for the product in food and beverages industry. Metal cans helps prolong shelf-life of perishable
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 with a 4.8% CAGR
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 …
The folding intermediate bulk containers (IBCs) market is on a growth trajectory, with an estimated value of US$ 418 million in 2022, projected to reach US$ 528 million by 2027, showcasing a Compound Annual Growth Rate (CAGR) of 4.8%. Remarkably, the China folding IBCs market defied initial pandemic-related skepticism and is anticipated to grow by 6.9% year on year in 2022. Despite global challenges, China's folding IBCs market is poised to contribute

All 5 Releases


More Releases for Myelo

Neutropenia Treatment Market to see Huge Growth by 2026 | Mylan, BeyondSpring, M …
Stay up-to-date and exploit latest trends of Neutropenia Treatment Market with latest edition released by AMA. Neutropenia Treatment Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Neutropenia Treatment industry with an attention on the Global market. The report gives key insights available status of the Neutropenia Treatment producers and is an important wellspring of direction and course for organizations and people
Chemotherapy Induced Thrombocytopenia Drugs Market In-Depth Analysis Of Competit …
Complete study of the global Chemotherapy Induced Thrombocytopenia Drugs market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Chemotherapy Induced Thrombocytopenia Drugs industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the
Chemotherapy Induced Thrombocytopenia Drugs Market: Competitive Dynamics & Globa …
LP INFORMATION offers a latest published report on Chemotherapy Induced Thrombocytopenia Drugs Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Chemotherapy Induced Thrombocytopenia Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million
Chemotherapy-Induced Myelosuppression Treatment Market Comprehensive Analysis 20 …
A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a subdued 3% y-o-y in 2019. Valued at nearly US$ 7 billion in 2018, gains are likely to be driven by a combination of multipronged factors, including, Development of natural product interventions for chemotherapy-induced side effects Growing implementation of radiation treatment in cancer treatment owing to the associated high success rate of chemotherapy Growing R&D investments
Thrombocytopenia Treatment Market Current Scenario and Future Growth Analysis by …
Thrombocytopenia Treatment Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Thrombocytopenia Treatment market research report is a professional and in-depth study on the current state of Thrombocytopenia Treatment Industry. The Thrombocytopenia Treatment Market research report covers the present scenario and the growth prospects of
Bronchitis Treatment Global Market Key Developments, Outlook, Analysis & Forecas …
Sedentary lifestyle, chemical pollutants, strict regulations to pollutant emission control, habit to cigarette smoke and adherence to a variety of international protocol are the major factors driving the market growth. Chemicals, smoke, air pollution and irritants are the risk factors for bronchitis. The most important indication of bronchitis is headache, continuous cough, nasal congestion, sore throat and fatigue. For more information about this report: http://www.reportsweb.com/bronchitis-treatment-global-market-outlook-2015-2022 Some of the key players in